Target Price | $85.14 |
Price | $84.59 |
Potential | 0.65% |
Number of Estimates | 22 |
22 Analysts have issued a price target Gilead Sciences 2025 . The average Gilead Sciences target price is $85.14. This is 0.65% higher than the current stock price. The highest price target is $123.00 45.41% , the lowest is $69.00 18.43% . | |
A rating was issued by 30 analysts: 15 Analysts recommend Gilead Sciences to buy, 14 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2025 of 0.65% . Most analysts recommend the Gilead Sciences stock at Purchase. |
22 Analysts have issued a sales forecast Gilead Sciences 2024 . The average Gilead Sciences sales estimate is $27.7b . This is 0.18% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $28.7b 3.20% , the lowest is $27.0b 2.80% .
This results in the following potential growth metrics:
2023 | $27.1b | 0.10% |
---|---|---|
2024 | $27.7b | 2.47% |
2025 | $28.0b | 0.97% |
2026 | $28.9b | 3.09% |
2027 | $29.9b | 3.64% |
2028 | $30.9b | 3.30% |
10 Analysts have issued an Gilead Sciences EBITDA forecast 2024. The average Gilead Sciences EBITDA estimate is $9.0b . This is 29.95% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $11.0b 14.89% , the lowest is $7.4b 42.17% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $12.4b | 3.29% |
---|---|---|
2024 | $9.0b | 27.47% |
2025 | $13.3b | 47.34% |
2026 | $13.5b | 1.25% |
2027 | $14.7b | 9.16% |
2028 | $15.4b | 5.17% |
2023 | 45.96% | 3.19% |
---|---|---|
2024 | 32.53% | 29.23% |
2025 | 47.47% | 45.93% |
2026 | 46.62% | 1.79% |
2027 | 49.11% | 5.34% |
2028 | 49.99% | 1.79% |
12 Gilead Sciences Analysts have issued a net profit forecast 2024. The average Gilead Sciences net profit estimate is $185m . This is 81.90% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $438m 57.13% , the lowest is $-685m 167.07% .
This results in the following potential growth metrics and future Net Margins:
2023 | $5.6b | 23.63% |
---|---|---|
2024 | $185m | 96.70% |
2025 | $6.6b | 3,488.46% |
2026 | $7.4b | 11.11% |
2027 | $7.8b | 6.27% |
2028 | $8.5b | 8.33% |
2023 | 20.72% | 23.75% |
---|---|---|
2024 | 0.67% | 96.77% |
2025 | 23.71% | 3,438.81% |
2026 | 25.55% | 7.76% |
2027 | 26.20% | 2.54% |
2028 | 27.48% | 4.89% |
12 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $0.15 . This is 81.71% lower than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $0.35 57.32% , the lowest is $-0.55 167.07% .
This results in the following potential growth metrics and future valuations:
2023 | $4.50 | 23.63% |
---|---|---|
2024 | $0.15 | 96.67% |
2025 | $5.33 | 3,453.33% |
2026 | $5.92 | 11.07% |
2027 | $6.29 | 6.25% |
2028 | $6.81 | 8.27% |
Current | 103.39 | 499.71% |
---|---|---|
2024 | 569.79 | 451.11% |
2025 | 15.88 | 97.21% |
2026 | 14.29 | 10.01% |
2027 | 13.45 | 5.88% |
2028 | 12.41 | 7.73% |
Based on analysts' sales estimates for 2024, the Gilead Sciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.49 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.80 .
This results in the following potential growth metrics and future valuations:
Current | 4.48 | 9.54% |
---|---|---|
2024 | 4.49 | 0.13% |
2025 | 4.44 | 0.96% |
2026 | 4.31 | 3.00% |
2027 | 4.16 | 3.51% |
2028 | 4.03 | 3.20% |
Current | 3.79 | 10.52% |
---|---|---|
2024 | 3.80 | 0.18% |
2025 | 3.76 | 0.96% |
2026 | 3.65 | 3.00% |
2027 | 3.52 | 3.51% |
2028 | 3.41 | 3.20% |
Gilead Sciences...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.